Striving to Quit-Wisconsin Tobacco Quit Line
|Smoking Cessation Smoking Nicotine Dependence||Behavioral: Incentives for abstinence and treatment engagement Behavioral: Attendance incentive|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
|Official Title:||Striving to Quit: Wisconsin Tobacco Quit Line Tobacco Cessation Research|
- Abstinence from smoking [ Time Frame: Measured 6 months after enrollment at follow-up assessment ]The data will be the biochemically confirmed reports of abstinence for the past 7 days (i.e., 7-day point-prevalence abstinence)
- Engagement in treatment [ Time Frame: Measured 12 months after enrollment at follow-up assessment ]The primary analyses will compare number of calls completed
- Cost-effectiveness [ Time Frame: Measured 12 months after enrollment ]The primary analysis will contrast the incremental costs of the treatment vs. attendance conditions by computing the Incremental Cost-Effectiveness Ratio (ICER) with regard to attaining 6-month abstinence.
|Study Start Date:||September 2012|
|Study Completion Date:||March 2013|
|Estimated Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
Experimental: Treatment incentives
Incentives for biochemical verification visits, treatment engagement, and abstinence
Behavioral: Incentives for abstinence and treatment engagement
Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
Active Comparator: Attendance incentive
Incentives for only attending the biochemical verification visits
Behavioral: Attendance incentive
Attendance Incentives - incentives for only attending the biochemical verification visits
Aim 1: To determine the extent to which contingent financial "treatment incentives" (i.e., incentives for biochemical verification visits, treatment engagement, and abstinence) versus "attendance incentives" (i.e., incentives for only attending the biochemical verification visits), increase rates of smoking cessation . Participants will be BadgerCare Plus tobacco users who enroll in Wisconsin Tobacco Quit Line (WTQL) services.
Aim 2: To determine the extent to which treatment incentives vs. attendance incentives increase rates of engagement in smoking cessation treatment through the WTQL when offered to BadgerCare Plus members who smoke.
Aim 3: To determine the cost‐effectiveness of the smoking cessation program when paired with treatment incentives and when paired with attendance incentives.
Aim 4: To identify moderating and mediational effects regarding the clinical benefit of incentivized smoking treatment
Aim 5: To determine the reach of an incentivized smoking cessation treatment that depends upon primary care clinic staff, a fax‐to‐quit referral mechanism and a state quit line.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01569477
|Principal Investigator:||Timothy B Baker, PhD||University of Wisconsin, Madison|